Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients

References

• Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM, Altmeyer R, Peiris JSM, et al. The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. J Virol. 2008;82(22):1–7. doi:10.1128/JVI.01052-08.
   Web of Science ®Google Scholar
• Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. doi:10.1080/22221751.2020.1719902.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RWsJr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Frenck RWsJr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–593. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725–1735. doi:10.1016/S0140-6736(21)00790-X.
   PubMed Web of Science ®Google Scholar
• Chen G, Li X, Sun M, Zhou Y, Yin M, Zhao B, Li X. COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says. Front Immunol. 2021;12:669010. doi:10.3389/fimmu.2021.669010.
   PubMed Web of Science ®Google Scholar
• Blumenthal KG, Robinson LB, Camargo CAsJr., Shenoy ES, Banerji A, Landman AB, Wickner P. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–1565. doi:10.1001/jama.2021.3976.
   PubMed Web of Science ®Google Scholar
• Krüttgen A, Lauen M, Klingel H, Imöhl M, Kleines M. Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273. J Virol Methods. 2022;299:114297. doi:10.1016/j.jviromet.2021.114297.
   PubMed Web of Science ®Google Scholar
• Azak E, Karadenizli A, Uzuner H, Karakaya N, Canturk NZ, Hulagu S. Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. Int J Infect Dis. 2021;113:58–64. doi:10.1016/j.ijid.2021.09.060.
   PubMed Web of Science ®Google Scholar
• Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E, Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin Microbiol Infect. 2020;26(11):1557.e1–1557.e7. doi:10.1016/j.cmi.2020.07.038.
   PubMed Web of Science ®Google Scholar
• Bayart JL, Douxfils J, Gillot C, David C, Mullier F, Elsen M, et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines (Basel). 2021;9.
   Web of Science ®Google Scholar
• Mattiuzzo G, Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, et al. Establishment of the WHO international standard and reference panel for anti-SARS-CoV-2antibody. WHO/BS.2020.2403: World Health Organization; 2020.
   Google Scholar
• Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–1348. doi:10.1016/S0140-6736(21)00527-4.
   PubMed Web of Science ®Google Scholar
• Ebisudani T, Sugimoto S, Haga K, Mitsuishi A, Takai-Todaka R, Fujii M, Toshimitsu K, Hamamoto J, Sugihara K, Hishida T, et al. Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. Cell Rep. 2021;35(10):109218. doi:10.1016/j.celrep.2021.109218.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang J, Xiao T, Lavine CL, Rawson S, Peng H, Zhu H, Anand K, Tong P, Gautam A, et al. Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. Science. 2021;373(6555):642–648. doi:10.1126/science.abi9745.
   PubMed Web of Science ®Google Scholar
• Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, De Virgilio A, De Marco F, Di Domenico EG, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. E Clin Med. 2021;36:100928. doi:10.1016/j.eclinm.2021.100928.
   Google Scholar
• Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci Ö, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science. 2021;371(6534):1152–1153. doi:10.1126/science.abg6105.
   PubMed Web of Science ®Google Scholar
• Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–141. doi:10.1038/s41586-021-03412-7.
   PubMed Web of Science ®Google Scholar
• Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y, Shemer-Avni Y, Rosenberg E, Taube R. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29(4):522–8.e2. doi:10.1016/j.chom.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature. 2021;600(7889):523–529. doi:10.1038/s41586-021-04085-y.
   PubMed Web of Science ®Google Scholar
• McDade TW, Demonbreun AR, Sancilio A, Mustanski B, D’Aquila RT, McNally EM. Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. Sci Rep. 2021;11(1):17325. doi:10.1038/s41598-021-96879-3.
   PubMed Web of Science ®Google Scholar
• Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386(1):35–46. doi:10.1056/NEJMoa2116298.
   PubMed Web of Science ®Google Scholar
• Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, Mollett G, Blacow RM, Peacock TP, Barclay WS, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog. 2021;17(12):e1010022. doi:10.1371/journal.ppat.1010022.
   PubMed Web of Science ®Google Scholar
• Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med. 2021;27(11):2025–2031. doi:10.1038/s41591-021-01527-y.
   PubMed Web of Science ®Google Scholar
• Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–94.e9. doi:10.1016/j.cell.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477–88.e4. doi:10.1016/j.chom.2021.01.014.
   PubMed Web of Science ®Google Scholar
• Pérez-Then E, Lucas C, Monteiro VS, Miric M, Brache V, Cochon L, Vogels CBF, Malik AA, De la Cruz E, Jorge A, et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022;28(3):481–485. doi:10.1038/s41591-022-01705-6.
   PubMed Web of Science ®Google Scholar
• Collier DA, Ferreira I, Kotagiri P, Datir RP, Lim EY, Touizer E, Meng B, Abdullahi A, Baker S, Dougan G, et al. Age-Related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–422. doi:10.1038/s41586-021-03739-1.
   PubMed Web of Science ®Google Scholar
• Kato H, Miyakawa K, Ohtake N, Go H, Yamaoka Y, Yajima S, Shimada T, Goto A, Nakajima H, Ryo A, et al. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay. J Infect Chemother. 2022;28(2):273–278. doi:10.1016/j.jiac.2021.11.021.
   PubMed Web of Science ®Google Scholar